Atara Biotherapeutics Investors May Be Eligible for Compensation in Securities Lawsuit

Investors who purchased securities of Atara Biotherapeutics between May 20, 2024, and January 9, 2026, may be entitled to compensation as part of a class action lawsuit. Rosen Law Firm, a prominent investor rights law firm, is reminding potential plaintiffs that the lead plaintiff deadline is May 22, 2026. The firm operates on a contingency fee basis, meaning no upfront costs are required for eligible investors. The lawsuit alleges securities violations during the specified period.